494 related articles for article (PubMed ID: 9698566)
1. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
Pisabarro MT; Serrano L; Wilmanns M
J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
[TBL] [Abstract][Full Text] [Related]
2. Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain.
Pisabarro MT; Serrano L
Biochemistry; 1996 Aug; 35(33):10634-40. PubMed ID: 8718852
[TBL] [Abstract][Full Text] [Related]
3. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the SH3 domain of betaPIX in complex with a high affinity peptide from PAK2.
Hoelz A; Janz JM; Lawrie SD; Corwin B; Lee A; Sakmar TP
J Mol Biol; 2006 Apr; 358(2):509-22. PubMed ID: 16527308
[TBL] [Abstract][Full Text] [Related]
6. Crystallization by capillary counter-diffusion and structure determination of the N114A mutant of the SH3 domain of Abl tyrosine kinase complexed with a high-affinity peptide ligand.
Cámara-Artigas A; Palencia A; Martínez JC; Luque I; Gavira JA; García-Ruiz JM
Acta Crystallogr D Biol Crystallogr; 2007 May; 63(Pt 5):646-52. PubMed ID: 17452790
[TBL] [Abstract][Full Text] [Related]
7. Structural studies of the phosphatidylinositol 3-kinase (PI3K) SH3 domain in complex with a peptide ligand: role of the anchor residue in ligand binding.
Batra-Safferling R; Granzin J; Mödder S; Hoffmann S; Willbold D
Biol Chem; 2010 Jan; 391(1):33-42. PubMed ID: 19919182
[TBL] [Abstract][Full Text] [Related]
8. Reexamination of the recognition preference of the specificity pocket of the Abl SH3 domain.
Santamaria F; Wu Z; Boulègue C; Pál G; Lu W
J Mol Recognit; 2003; 16(3):131-8. PubMed ID: 12833568
[TBL] [Abstract][Full Text] [Related]
9. The crystal structure of the N-terminal SH3 domain of Grb2.
Guruprasad L; Dhanaraj V; Timm D; Blundell TL; Gout I; Waterfield MD
J Mol Biol; 1995 May; 248(4):856-66. PubMed ID: 7752246
[TBL] [Abstract][Full Text] [Related]
10. The C-terminal SH3 domain of p67phox binds its natural ligand in a reverse orientation.
Finan P; Koga H; Zvelebil MJ; Waterfield MD; Kellie S
J Mol Biol; 1996 Aug; 261(2):173-80. PubMed ID: 8757285
[TBL] [Abstract][Full Text] [Related]
11. Examining the specificity of Src homology 3 domain--ligand interactions with alkaline phosphatase fusion proteins.
Yamabhai M; Kay BK
Anal Biochem; 1997 Apr; 247(1):143-51. PubMed ID: 9126384
[TBL] [Abstract][Full Text] [Related]
12. High-resolution structure of the diphtheria toxin repressor complexed with cobalt and manganese reveals an SH3-like third domain and suggests a possible role of phosphate as co-corepressor.
Qiu X; Pohl E; Holmes RK; Hol WG
Biochemistry; 1996 Sep; 35(38):12292-302. PubMed ID: 8823163
[TBL] [Abstract][Full Text] [Related]
13. The high-resolution NMR structure of the R21A Spc-SH3:P41 complex: understanding the determinants of binding affinity by comparison with Abl-SH3.
Casares S; Ab E; Eshuis H; Lopez-Mayorga O; van Nuland NA; Conejero-Lara F
BMC Struct Biol; 2007 Apr; 7():22. PubMed ID: 17407569
[TBL] [Abstract][Full Text] [Related]
14. SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef.
Hiipakka M; Poikonen K; Saksela K
J Mol Biol; 1999 Nov; 293(5):1097-106. PubMed ID: 10547288
[TBL] [Abstract][Full Text] [Related]
15. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
[TBL] [Abstract][Full Text] [Related]
16. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
[TBL] [Abstract][Full Text] [Related]
17. SH3 domains and drug design: ligands, structure, and biological function.
Dalgarno DC; Botfield MC; Rickles RJ
Biopolymers; 1997; 43(5):383-400. PubMed ID: 9566119
[TBL] [Abstract][Full Text] [Related]
18. A miniprotein scaffold used to assemble the polyproline II binding epitope recognized by SH3 domains.
Cobos ES; Pisabarro MT; Vega MC; Lacroix E; Serrano L; Ruiz-Sanz J; Martinez JC
J Mol Biol; 2004 Sep; 342(1):355-65. PubMed ID: 15313630
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of PxxDY motif recognition in SH3 binding.
Aitio O; Hellman M; Kesti T; Kleino I; Samuilova O; Pääkkönen K; Tossavainen H; Saksela K; Permi P
J Mol Biol; 2008 Sep; 382(1):167-78. PubMed ID: 18644376
[TBL] [Abstract][Full Text] [Related]
20. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
Reichman C; Singh K; Liu Y; Singh S; Li H; Fajardo JE; Fiser A; Birge RB
Oncogene; 2005 Dec; 24(55):8187-99. PubMed ID: 16158059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
